1. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
- Author
-
Demichelis, F., Fall, K., Perner, S., Andrén, O., Schmidt, F., Setlur, S. R., Hoshida, Y., Mosquera, J.-M., Pawitan, Y., Lee, C., Adami, H.-O., Mucci, L. A., Kantoff, P. W., Andersson, S.-O., Chinnaiyan, A. M., Johansson, J.-E., and Rubin, M. A.
- Subjects
- *
GENE fusion , *PROSTATE cancer , *FUSION (Phase transformation) , *TUMORS , *PROSTATE , *POLYMERASE chain reaction - Abstract
The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3–5.8). Quantitative reverse-transcription–polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.Oncogene (2007) 26, 4596–4599; doi:10.1038/sj.onc.1210237; published online 22 January 2007 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF